Study guide
11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing
AACVPR CCRP Certified Cardiac Rehab Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Cardiac Rehabilitation Foundations
1.1 AACVPR CCRP Credential, Exam Specifications & Core Competencies 1.2 Phases of Cardiac Rehabilitation & Clinical Delivery Models 1.3 Interdisciplinary Team Roles, Clinical Scope of Practice & Safety
2 Chapter 2: Cardiovascular Anatomy, Physiology & Pathology
2.1 Cardiac Anatomy, Coronary Circulation & Hemodynamics 2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization 2.3 Heart Failure (HFrEF/HFpEF), Cardiomyopathies & Valvular Heart Disease 2.4 Electrical Interventions: Cardioversion, Catheter Ablation & Post-Procedure Rehabilitation
3 Chapter 3: Diagnostic Evaluation, ECG & Clinical Testing
3.1 Baseline Clinical Assessment & AACVPR Risk Stratification 3.2 12-Lead ECG Interpretation: Ischemia, Transmural Infarction & Conduction 3.3 Cardiac Arrhythmias, Conduction Blocks & Device Rhythms (Pacemakers/ICDs) 3.4 Graded Exercise Testing (GXT), Gas Exchange & Termination Criteria
4 Chapter 4: Patient-Centered Assessment: Education, Equity & Social Context
4.1 Learning Readiness: Health Literacy, Learning Styles & Communication Barriers 4.2 Social Determinants of Health, Culture & Spirituality in Cardiac Rehab 4.3 Sex- and Race-Based Differences in Cardiovascular Presentation & Outcomes 4.4 Substance Use Screening: Alcohol, Cannabis, Stimulants & Cardiac Risk
5 Chapter 5: Exercise Prescription & Aerobic Conditioning
5.1 FITT-VP Framework & Aerobic Exercise Intensity Calculation 5.2 Exercise Progression, Environmental Factors & Telemetry Monitoring Guidelines 5.3 High-Intensity Interval Training (HIIT) vs Moderate Continuous Training (MICT) 5.4 Home Exercise Program Design, Prescription & Independent Progression
6 Chapter 6: Exercise Physiology, Monitoring & Session Design
6.1 Health-Related Physical Fitness Components & Functional Capacity Testing 6.2 Acute Cardiovascular Responses to Aerobic Exercise: METs, Rate Pressure Product & VO₂ 6.3 Chronic Training Adaptations in Cardiac Patients 6.4 Structuring the Exercise Session: Warm-Up, Conditioning & Cool-Down 6.5 ECG Telemetry Setup: Skin Preparation, Electrode Placement & Artifact Troubleshooting 6.6 Pulse Oximetry, Exertional Desaturation & Supplemental Oxygen Titration
7 Chapter 7: Resistance, Flexibility & Exercise Safety
7.1 Resistance Training Guidelines, Hemodynamics & Sternal Precautions 7.2 Flexibility, Neuromotor Training & Special CR Populations 7.3 Exercise Contraindications, Adverse Signs/Symptoms & Emergency Protocols
8 Chapter 8: Physical Activity Counseling & Behavior Change
8.1 Physical Activity Guidelines, Sedentary Physiology & NEAT 8.2 Behavioral Change Theories: Transtheoretical Model & Social Cognitive Theory 8.3 Motivational Interviewing Principles & Resolving Ambivalence 8.4 SMART Goal Setting, Activity Tracking & Relapse Prevention
9 Chapter 9: Physical Activity Assessment & Real-World Activity Counseling
9.1 Physical Activity vs Exercise: Assessment Instruments, Logs & Wearables 9.2 Metabolic Requirements of Daily Life: Occupational, Recreational & Sexual Activity 9.3 Environmental & Situational Risk: Heat, Cold, Altitude, Air Quality & High-Risk Activities 9.4 Upper- vs Lower-Body Physiologic Demands & Modality Selection
10 Chapter 10: Hypertension & Blood Pressure Regulation
10.1 2017 ACC/AHA Hypertension Classification & Cardiovascular Risk 10.2 Antihypertensive Pharmacology & Exercise Hemodynamics 10.3 Exertional Blood Pressure Dynamics, Exertional Hypotension & Crisis 10.4 Home Blood Pressure Monitoring, Sodium Restriction & Lifestyle Interventions 10.5 Blood Pressure Measurement Technique, Device Validation & Renal Protection
11 Chapter 11: Diabetes Mellitus & Metabolic Regulation
11.1 Diabetes Pathophysiology, Diagnostic Criteria & Glycemic Targets 11.2 Antidiabetic Pharmacotherapy (Insulin, Sulfonylureas, SGLT2i, GLP-1 RA) 11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia 11.4 Diabetic Complications & Exercise Adaptations (Autonomic & Peripheral Neuropathy) 11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing 11.6 Diabetic Foot Care, Skin Integrity & Footwear Assessment
12 Chapter 12: Blood Lipid Management & Atherosclerosis Prevention
12.1 Lipid Metabolism, Atherogenic Lipoproteins & Advanced Lipid Testing 12.2 Statin Therapy, Dosing Intensity & Secondary Prevention Targets 12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
13 Chapter 13: Medical Nutrition Therapy & Dietary Patterns
13.1 Nutritional Assessment & Macronutrient Guidelines in Cardiovascular Disease 13.2 Cardioprotective Dietary Patterns: Mediterranean, DASH & Plant-Based 13.3 Dietary Lipids, Sodium, Soluble Fiber & Plant Stanols/Sterols 13.4 Clinical Scope: CR Professional Counseling Boundaries vs RD/RDN Referral
14 Chapter 14: Body Composition & Weight Management
14.1 Anthropometric Assessment: BMI, Waist Circumference & Obesity Paradox 14.2 Behavioral Weight Management, Energy Balance & Caloric Deficits 14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
15 Chapter 15: Tobacco Cessation Interventions
15.1 Cardiovascular Pathophysiology of Tobacco, Nicotine & Secondhand Smoke 15.2 Clinical Cessation Frameworks: The 5 A's & 5 R's Models 15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion 15.4 Behavioral Counseling, Coping Strategies & Relapse Prevention
16 Chapter 16: Psychosocial Health, Screening & Behavioral Support
16.1 Psychosocial Risk Factors & Prognostic Impact in Heart Disease 16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration 16.3 Evidence-Based Interventions: Stress Management, CBT Principles & Social Support 16.4 Crisis Protocols, Suicidal Ideation & Mental Health Referral Pathways 16.5 Psychotropic Pharmacology & Cardiac Safety 16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
17 Chapter 17: Regulatory Compliance, Documentation & Program Outcomes
17.1 CMS Coverage Guidelines, Qualifying Diagnoses & Practitioner Supervision 17.2 Individualized Treatment Plan (ITP) Components, 30-Day Updates & Goals 17.3 AACVPR Outcome Domains & Program Certification Performance Measures 17.4 Program Certification, Quality Improvement & Medical Emergency Preparedness
11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing
Key Takeaways Explain This Topic AI
Patients on insulin or sulfonylureas require a glucose check before exercise; a value below roughly 100 mg/dL warrants 15 to 30 grams of carbohydrate with a recheck before starting.
Continuous glucose monitors read interstitial fluid and lag blood glucose by roughly 5 to 15 minutes, so trend arrows matter more than the displayed number during rapidly changing states such as exercise.
Time in range of 70 to 180 mg/dL with a goal above 70%, time below 70 mg/dL under 4%, and time below 54 mg/dL under 1% are the standard CGM targets.
Delayed post-exercise hypoglycemia can occur up to 24 hours after a session, with the greatest risk overnight following afternoon or evening exercise.
Any symptom-device mismatch, or a CGM reading during rapid change, should be confirmed with a fingerstick before acting.
Last updated: September 2026
11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing
Note
Blueprint anchors : Domain 6 (Diabetes Management), task 6.9 — Educate on the clinical importance of monitoring blood glucose values before and after exercise ; and task 6.10 — Educate on home blood glucose monitoring and management .
Exercise is a glucose-lowering intervention, and in a patient taking insulin or an insulin secretagogue it is a glucose-lowering intervention that the medication does not know is happening. Peri-exercise glucose monitoring is the safeguard, and interpreting the data — increasingly from a continuous sensor rather than a fingerstick — is a daily CR competency.
Who Requires Pre-Exercise Testing
Mandatory before every session for patients on insulin or insulin secretagogues (sulfonylureas such as glipizide, glyburide, glimepiride, and meglitinides) — the agents that cause hypoglycemia. Patients on metformin, SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors alone do not typically require routine pre-exercise testing because these agents rarely cause hypoglycemia in monotherapy, though testing remains appropriate when symptoms occur or a combination regimen includes a hypoglycemic agent.
Pre-Exercise Thresholds
- Pre-exercise glucose Action
- < 70 mg/dL Treat hypoglycemia with the Rule of 15; do not exercise until resolved and stable
70-100 mg/dL Consume 15-30 g of carbohydrate , recheck in 15 minutes, and proceed once rising and above threshold
100-250 mg/dL Generally safe to proceed
> 250 mg/dL with ketones (particularly type 1) Do not exercise ; exercise worsens ketosis; notify the physician
> 250-300 mg/dL without ketones Proceed with caution; assess hydration and symptoms; consider deferring at higher values per program protocol
Warning
The reason exercise is withheld with hyperglycemia plus ketones is that a relative insulin deficiency prevents muscle from taking up glucose, while exercise-induced counterregulatory hormones drive further hepatic glucose output and lipolysis — so glucose and ketones both rise. This is the opposite of the usual glucose-lowering effect and is a common exam distinction.
Post-Exercise Testing and Delayed Hypoglycemia
Check glucose after the session in all patients on insulin or secretagogues.
Important
Delayed post-exercise hypoglycemia can occur up to 24 hours after exercise , driven by ongoing replenishment of muscle and hepatic glycogen and by increased insulin sensitivity that persists roughly 24 to 72 hours after a single bout. The highest-risk window is overnight following afternoon or evening exercise . Patients must be taught to check before bed after an exercise day, to consider a bedtime snack when the reading is low-normal, and to be aware that nocturnal hypoglycemia may present only as night sweats, vivid dreams, or a morning headache. Alcohol compounds this risk by suppressing hepatic gluconeogenesis.
Always carry rapid-acting carbohydrate at every session and instruct patients to carry it during independent exercise.
- Self-Monitoring of Blood Glucose (SMBG)
- Technique points worth teaching
Wash hands with soap and water and dry — alcohol wipes leave residue and food residue on fingers is a classic cause of spuriously high readings.
Lance the side of the fingertip , not the pad, which is more sensitive and more used.
Rotate sites; alternate-site testing (palm, forearm) lags during rapid change and should not be used when hypoglycemia is suspected.
Check strip expiration and store strips in their sealed vial away from heat and humidity.
Code the meter if required, and bring the meter to appointments for download and comparison.
Frequency
Determined by regimen: multiple daily doses of insulin require testing before meals and at bedtime, plus before exercise and driving; basal-only or oral regimens require far less. The purpose of testing is to generate actionable patterns , so if the patient cannot say what they do differently based on a result, the testing schedule needs revision by the prescriber.
Continuous Glucose Monitoring
CGM systems measure glucose in interstitial fluid via a subcutaneous sensor and report values every few minutes with directional trend arrows.
The lag
Important
Interstitial glucose lags blood glucose by roughly 5 to 15 minutes . During periods of rapid change — precisely what exercise creates — the displayed number can meaningfully misstate the current blood value. A CGM reading 95 mg/dL with a rapidly falling arrow during exercise may correspond to a blood glucose already below 70. Treat the trend, not just the number , and confirm with a fingerstick whenever symptoms and device disagree.
Standard metrics
- Metric Target
- Time in range (70-180 mg/dL) Above 70%
- Time below range (< 70 mg/dL) Under 4%
- Time below 54 mg/dL Under 1%
- Time above range (> 180 mg/dL) Under 25%
- Glucose Management Indicator (GMI) Estimated A1C equivalent from mean glucose
- Coefficient of variation 36% or less indicates acceptable glycemic variability
Time in range is a far more actionable target for a CR conversation than A1C, because it responds within days and it separates a patient with a "good" A1C achieved by averaging severe highs and lows from one with genuinely stable control.
Practical CGM issues in a rehab gym
Compression lows — lying or pressing on the sensor produces a false low reading; a common cause of alarms during floor exercises or mat work.
Sensor placement away from areas contacted by equipment, straps, or telemetry belts.
Acetaminophen interference affects some older sensor generations, falsely elevating readings.
Alarms can be set for predictive low alerts, which is genuinely useful for peri-exercise safety.
The first 24 hours after insertion are typically less accurate.
Realistic Clinical Scenario
Scenario : A 61-year-old man with type 2 diabetes on basal insulin and glimepiride wears a CGM. He arrives for a 4:00 PM session; his CGM reads 108 mg/dL with a downward-trending arrow. He feels fine and wants to start. He mentions that last week he woke at 3:00 AM drenched in sweat after an afternoon session and assumed it was the room temperature.
Analysis : Two issues. First, a CGM value of 108 with a falling arrow before exercise is not the same as a stable 108 — interstitial lag means his blood glucose may already be lower and is heading down, and exercise will accelerate the fall. Second, the 3:00 AM sweating episode after an afternoon session is a textbook description of nocturnal hypoglycemia from delayed post-exercise glucose lowering, amplified by both basal insulin and a sulfonylurea. He misattributed it, which means it is likely to recur.
Plan : Before starting today, confirm with a fingerstick given the falling trend and symptom-free state, and provide 15 to 30 g of carbohydrate with a recheck rather than beginning at a falling low-normal value. Teach the trend-arrow principle explicitly: the arrow governs the decision, not the number alone. Address the nocturnal episode directly — name it as probable hypoglycemia rather than room temperature, instruct him to check before bed on exercise days, discuss a bedtime snack when the pre-bed value is low-normal, and set a predictive low alarm on his CGM. Report both the pre-exercise pattern and the nocturnal episode to the prescriber, since basal insulin or glimepiride dose adjustment on exercise days is a prescriber decision and sulfonylureas carry particular nocturnal hypoglycemia risk. Document in the ITP and re-assess at the 30-day update.